UnknownNot Applicable

Impact and Influence of the Use of Hypnosis Adapted to People With Severe Stage Neurocognitive Disorder (HAPNeSS) on the Professional Practices of EHPAD (Establishment for Dependent Elderly People) Caregivers With Elderly Residents

France36 participantsStarted 2024-09

Plain-language summary

The aim of this study is to propose a non-anxiety-inducing method of managing behavioral disorders for patients and healthcare professionals. The main objective of this study is to evaluate the implementation, use and effects of HAPNeSS (Hypnosis Adapted to People with Severe Neurocognitive Disorders) training on the management of residents aged over 75 with moderately severe to severe Alzheimer's disease or a related disorder, who may present behavioral disorders, with caregivers working in EHPAD.

Who can participate

Age range

18 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: EHPAD staff meeting the following criteria will be included in the study: * Nurses, care assistants, gerontological care assistants, psychologists, coordinating physicians, psychomotor therapists, occupational therapists; * More than one year's experience in the structure. The study will examine the individual perceptions of EHPAD professionals of patients meeting the following criteria: * Be a resident of an EHPAD ; * suffering from a moderately severe or severe major neurocognitive disorder; * over 75 years of age. Exclusion Criteria: EHPAD professionals will not be included: * Not fluent in French, * Not wishing to be trained in hypnosis. The individual perception of EHPAD professionals of patients meeting these criteria will not be questioned in the study: * Minor neurocognitive impairment, major neurocognitive impairment at a mild or moderate stage, or no cognitive impairment; * under 75 years of age.

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Impact of HAPNeSS on the management of work situations involving behavioral disorders.

Timeframe: Month 2 and month 6

Trial details

NCT IDNCT06535763

SponsorUniversity Hospital, Bordeaux

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2025-03

Contact for this trial

Marie FLOCCIA, MD

+33556795679 marie.floccia@chu-bordeaux.fr

View on ClinicalTrials.gov More Alzheimer Disease trials